Nucleai For Profit
Step into the World of AI-Driven Spatial Biomarkers. Your next-gen cancer treatments need better companions. Advance your ADC, bispecific, and immunotherapy programs with a next-gen diagnostic strategy. Join us at IO360
Founded Date:
2017-01-01
Last Funding Type:
Series B
Headquarters:
Tel Aviv, Tel Aviv, Israel
Investors Number:
7
Technology:
AI-driven
Employee Number:
51-100
Industry:
Deep Diagnostics
Estimated Revenue:
$4.8Mper year
Last Funding Date:
2022-03-22
Funding Status:
Early Stage Venture
Total Funding:
46500000